Results 11 to 20 of about 19,408 (193)

The assessment of therapeutic response of oropharyngeal and oesophageal candidiasis in AIDS using a new scoring system: studies with D0870. [PDF]

open access: yes, 1999
We developed and compared five scoring systems designed to quantitate therapeutic response in cases of oropharyngeal candidiasis. We utilized prospectively collected data on 114 patients treated with several doses of the azole D0870.
Williams, Keith   +5 more
core   +4 more sources

Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles

open access: yes, 2022
When used in combination with azole antifungal drugs, cyclooxygenase (COX) inhibitors such as ibuprofen improve antifungal efficacy. We report the conjugation of a chiral antifungal azole pharmacophore to COX inhibitors and the evaluation of activity of ...
Pallabita Basu (12009955)   +2 more
core   +2 more sources

A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi [PDF]

open access: yes, 2013
Introduction: Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to ...
Mavuto Mukaka   +49 more
core   +1 more source

A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. [PDF]

open access: yes, 2014
OBJECTIVE: We have previously reported high ten-week mortality from cryptococcal meningitis in Malawian adults following treatment-induction with 800 mg oral fluconazole (57% [33/58]).
Allain, TJ   +52 more
core   +1 more source

AMBITION-cm : intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa : study protocol for a randomized controlled trial [PDF]

open access: yes, 2015
Cryptococcal meningitis (CM) is a leading cause of mortality among HIV-infected individuals in Africa. Poor outcomes from conventional antifungal therapies, unavailability of flucytosine, and difficulties administering 14 days of amphotericin B are key ...
Leeme, Tshepo   +50 more
core   +2 more sources

Ibuprofen-Mediated Reversal of Fluconazole Resistance in Clinical Isolates of Candida [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2015
Introduction: In view of the increasing prevalence of invasive Candidiasis in today’s health-care scenario and the emergence of fluconazole resistance among clinical isolates of Candida, we sought to determine if Ibuprofen could elicit a reversal of ...
Monika Sharma   +6 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study [PDF]

open access: yes, 2013
Background: Candida spp. are a frequent cause of nosocomial bloodstream infections worldwide. Objective: To evaluate the use patterns and outcomes associated with intravenous (IV) fluconazole therapy in intensive care units in Spain and Germany ...
Wissing, Heimo   +7 more
core   +1 more source

Fluconazole Resistance and Virulence in In Vitro Induced-Fluconazole Resistant Strains and in Clinical Fluconazole Resistant Strain of Cryptococcus deuterogattii

open access: yesPathogens, 2023
Neuromeningeal cryptococcosis is a life-threatening infection of the central nervous system, caused by encapsulated yeast belonging to the Cryptococcus neoformans and Cryptococcus gattii species complexes. Recent data showed that virulence and antifungal
Sébastien Bertout   +5 more
doaj   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Home - About - Disclaimer - Privacy